According to a new study, Teriflunomide delays the autoimmune disease's early signs. Teriflunomide reduced MS onset by 72%.
Patients whose MRIs show signs of multiple sclerosis (MS) may benefit from starting treatment with teriflunomide before the onset of symptoms. The study's preliminary results will be presented in Boston at the 75th Annual Meeting of the American Academy of Neurology, April 22-27, 2023, and simultaneously online. The announcement of the study came out on April 19, 2023. Radiologically isolated syndrome is a condition that affects people with brain or spinal cord lesions but no other MS symptoms.
Myelin, the fatty, white sheath that surrounds neurons, is destroyed in people with multiple sclerosis because of an overactive immune response. Symptoms of multiple sclerosis (MS) include exhaustion, numbness, tingling, and trouble walking. Christine Lebrun Frenay, MD, of the University Hospital of Nice in France, and a Fellow of the American Academy of Neurology, said, "These cases are being discovered as more and more people are having brain scans for various reasons, such as headache or head trauma, and many of these people go on to develop MS."
One's chances of avoiding permanent neurologic impairment and disabling symptoms due to multiple sclerosis improve if treatment begins as soon as possible. A total of 89 patients with a radiologically isolated disease participated in the research. In one group, teriflunomide 14 mg once daily was used while in the other group, a placebo was used. Two years were devoted to the investigation.
In a comparison between those who took the real drug and those who took a placebo, eight people who took the real drug developed MS. Teriflunomide was found to have a 72% reduced risk of causing initial symptoms than the placebo after controlling for all other covariates. Radiologically isolated syndrome (RIS) is the asymptomatic stage of multiple sclerosis, and "our findings suggest that early intervention with teriflunomide may benefit those diagnosed with RIS," as stated by Lebrun Frenay. However, findings require more detailed research. MRIs can only be used to diagnose multiple sclerosis in high-risk patients.
